NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition-Reference-Cited by-同舟云学术

NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition

Published:2022-07 Issue:13 Volume:82 Page:2472-2489.e8
ISSN:1097-2765
Container-title:Molecular Cell
language:en
Short-container-title:Molecular Cell

Author:

Drosos Yiannis,Myers Jacquelyn A.,Xu Beisi,Mathias Kaeli M.,Beane Emma C.,Radko-Juettner Sandi,Mobley Robert J.,Larsen Margaret E.,Piccioni Federica,Ma Xiaotu,Low Jonathan,Hansen Baranda S.,Peters Samuel T.,Bhanu Natarajan V.,Dhanda Sandeep K.,Chen Taosheng,Upadhyaya Santhosh A.,Pruett-Miller Shondra M.,Root David E.,Garcia Benjamin A.,Partridge Janet F.,Roberts Charles W.M.

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology

Reference73 articles.

1. The molecular hallmarks of epigenetic control;Allis;Nat. Rev. Genet.,2016

2. The SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers;Alver;Nat. Commun.,2017

3. The role of nuclear receptor–binding SET domain family histone lysine methyltransferases in cancer;Bennett;Cold Spring Harbor Perspect. Med.,2017

4. A workflow for ultra-rapid analysis of histone post-translational modifications with direct-injection mass spectrometry;Bhanu;Bio Protoc.,2020

5. CpG islands recruit a histone H3 lysine 36 demethylase;Blackledge;Mol. Cell,2010

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis;Nature Genetics;2024-09-09

2. PPARγ and C/EBPα enable adipocyte differentiation upon inhibition of histone methyltransferase PRC2 in malignant tumors;Journal of Biological Chemistry;2024-09

3. Assessment of SWI/SNF chromatin remodeling complex related genes as potential biomarkers and therapeutic targets in pan-cancer;Molecular Cancer;2024-08-27

4. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes;Nature Communications;2024-08-08

5. Chromatin remodellers as therapeutic targets;Nature Reviews Drug Discovery;2024-07-16